Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

PCOS Peptide Therapy: Clinical Comparison

Semaglutide (Ozempic, Wegovy) GLP-1 receptor agonist. Slows gastric emptying, reduces appetite, improves insulin sensitivity Effective for metabolic PCOS phenotype; reduces visceral fat and fasting insulin by 30–40% 1.0–2.4mg weekly subcutaneous Modest (12–15%

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Semaglutide (Ozempic, Wegovy)
  • GLP-1 receptor agonist. Slows gastric emptying, reduces appetite, improves insulin sensitivity
  • Effective for metabolic PCOS phenotype; reduces visceral fat and fasting insulin by 30–40%
  • 1.0–2.4mg weekly subcutaneous
  • Modest (12–15% total testosterone reduction)
  • Best first-line option for insulin-resistant PCOS without severe hyperandrogenism. Well-tolerated, extensive safety data
  • Tirzepatide (Mounjaro, Zepbound)
  • Dual GLP-1/GIP agonist. Enhances insulin secretion, reduces glucagon, increases energy expenditure
  • Superior androgen suppression; restores ovulation in 60–70% of anovulatory PCOS patients
  • 5–15mg weekly subcutaneous
  • Significant (20–28% total and free testosterone reduction)
  • Preferred for hyperandrogenic PCOS with hirsutism or acne; dual mechanism addresses both insulin resistance and ovarian androgen synthesis
  • Tesamorelin
  • Growth hormone-releasing hormone analog. Reduces visceral adipose tissue
  • Targets central adiposity common in PCOS; no direct effect on insulin or androgens
  • 2mg daily subcutaneous
  • None
  • Adjunct therapy for visceral fat reduction; does not address core PCOS pathology; requires combination with insulin sensitizers
  • CJC-1295 + Ipamorelin
  • Growth hormone secretagogue combination. Stimulates pulsatile GH release
  • Improves body composition and metabolic rate; indirect insulin sensitivity benefit
  • 200–300mcg each, 5 days/week subcutaneous
  • Indirect (via improved insulin sensitivity)
  • Best as secondary intervention after GLP-1 therapy establishes baseline metabolic control; not first-line for PCOS
  • Tesofensine
  • Triple monoamine reuptake inhibitor. Increases norepinephrine, dopamine, serotonin
  • Appetite suppression and thermogenesis; no insulin sensitization
  • 0.25–1.0mg daily oral
  • Investigational; lacks PCOS-specific trial data; consider only after GLP-1 agonists show inadequate response

Related resources

More comparisons